{"id":"NCT01768572","sponsor":"Sanofi","briefTitle":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","officialTitle":"A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2013-01-15","resultsPosted":"2017-06-26","lastUpdate":"2017-06-26"},"enrollment":202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"sarilumab SAR153191 (REGN88)","otherNames":[]},{"type":"DRUG","name":"tocilizumab","otherNames":[]},{"type":"DRUG","name":"hydroxychloroquine","otherNames":[]},{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"sulfasalazine","otherNames":[]},{"type":"DRUG","name":"leflunomide","otherNames":[]},{"type":"DRUG","name":"subcutaneous placebo","otherNames":[]},{"type":"DRUG","name":"intravenous placebo","otherNames":[]}],"arms":[{"label":"Sarilumab 150 mg q2w","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg q2w","type":"EXPERIMENTAL"},{"label":"Tocilizumab q4w","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 211 days","effectByArm":[{"arm":"Sarilumab 150 mg q2w","deltaMin":33,"sd":null},{"arm":"Sarilumab 200 mg q2w","deltaMin":36,"sd":null},{"arm":"Tocilizumab q4w","deltaMin":68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":78,"countries":["United States","Argentina","Belgium","Brazil","Czechia","Estonia","Finland","Hungary","Israel","Italy","Mexico","Netherlands","Norway","Poland","Romania","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["34519964","32453485","30590833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["Neutropenia","Nasopharyngitis","Accidental overdose","Urinary tract infection","Upper respiratory tract infection"]}}